Pets need healthcare too while many humans neglect to treat early stages of diseases. Zomedica Pharmaceuticals (NYSE: ZOM) is one of the few veterinary based pharmaceutical companies that develop medicines for rare animal diseases.
Until the fall of 2018 ZOM had enjoyed riding higher than $2.00 but the steep recession could happen due to negative earnings that chase long term investors’ away. However, Zomedica seems to finish its cash-burning style of business.
In the long run, ZOM is falling sharply as stockholders do not pay much attention to the healthcare of animals. Perhaps, it is occurring because of COVID-19 that makes anyone self-centered to survive the deadly virus.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.